α2β1 integrin

α2β1 Integrin Ligand Peptide TFA interacts with integrin receptors on the cell membrane, mediating extracellular signaling and potentially acting as an antagonist of the collagen receptor.

The Asp-Gly-Glu-Ala (DGEA) amino acid domain of type I collagen interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.

α2β1 Integrin Ligand Peptide acetate (α2β1 Integrin Ligand Peptide acetate (134580-64-6)) is a potential antagonist of α2β1 integrin receptor. α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells.

αLβ2integrin-IN-1 (example 1) is an inhibitor of cell adhesion mediated by αLβ2 integrin and can be utilized for studying inflammatory conditions associated with αLβ2 integrin.

αMβ2integrinagonist-1 (Compound 8) is a highly selective αMβ2 integrin agonist with anti-inflammatory properties (EC50=1.4 nM). It activates integrin-mediated cell adhesion and the JNK/ERK signaling pathway. Additionally, αMβ2integrinagonist-1 induces polarization of tumor-associated macrophages and enhances antitumor T-cell immune responses. This compound holds potential for research in cancer and chronic inflammatory diseases such as pancreatic cancer and rheumatoid arthritis.

α5β1integrin agonist-2 (Compound 2) is a highly selective agonist of the α5β1 integrin, with an EC50 of 45.98 nM. It enhances extracellular matrix adhesion and activates the Akt/ERK signaling pathways. This compound shows potential for research in ischemic stroke.

αvβ1 integrin-IN-2 (compound 32) is a potent inhibitor of ανβ1 and α5β1 integrins, exhibiting IC50 values of 0.9 nM and 33 nM, respectively. This compound also inhibits other integrins with IC50 values of 380 nM (ανβ3), 280 nM (ανβ5), 230 nM (ανβ6), and 87 nM (ανβ8), as determined by the SPRA assay [1].

2-Methylbutyrylcarnitine (chloride) acts as a gut microbial metabolite that targets integrin α2β1 on platelets, facilitating the activation of cytosolic phospholipase A2 (cPLA2) and enhancing platelet hyperresponsiveness. This compound further augments platelet hyperreactivity and promotes thrombus formation in mice. It is also characterized as a branched-chain acylcarnitine.

BTT-3034, a sulfonamide derivative, functions as an α2β1 integrin inhibitor. It effectively inhibits cell adhesion to rat tail collagen I, with an EC50 value of 160 nM and an Emax value of 86%. Additionally, BTT-3034 impedes collagen binding through the α2 variant carrying the conformation-activating E318W mutation.

α2β1 integrin inhibitor

BTT-3033 is an orally active and potent α2β1 (EC50: 130 nM) inhibitor with an affinity for the α2I domain, inhibiting platelet binding to collagen I and cell proliferation. BTT-3033 induces apoptosis and can be used to study prostate cancer, inflammation, and cardiovascular disease.

Vatelizumab is a humanised monoclonal antibody targeting Integrin α2β1 (very late antigen 2, VLA-2, CD49b), which enhances the frequency of regulatory T cells via the p38 MAPK signalling pathway and can be used for research into multiple sclerosis.

Highly potent integrin α1β1 inhibitor (IC50 = 0.8 nM for α1β1 binding to type IV collagen). Selective for α1β1 over α2β1, αIIbβ3, αvβ3, α4β1, α5β6, α9β1 and α4β7. Inhibits FGF2-stimulated angiogenesis in the chicken chorioallantoic model. Displays antitum

VSLRGDTRG is a synthetic peptide derived from the RGD motif in cadherin17 (CDH17) that binds to the α2β1 integrin, activating its signaling pathways. By promoting high-affinity conformational changes in β1 integrins through the RGD motif, VSLRGDTRG enhances cell adhesion and the phosphorylation of FAK and ERK1/2, thereby driving tumor proliferation and metastasis. This peptide is useful for research on cancers expressing CDH17, such as colorectal and pancreatic cancer.

VSLRGDTRG acetate is a synthetic peptide of the RGD motif from cadherin17 (CDH17), capable of binding to α2β1 integrin and activating its signaling pathways. It facilitates the high-affinity conformational change of β1 integrin via the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby promoting tumor proliferation and metastasis. VSLRGDTRG acetate is applicable in research on cancers expressing CDH17, such as colon and pancreatic cancers.

GFOGER peptide is an integrin ligand peptide for α2β1, α1β1, and α11β1. It is recognized through direct interaction with integrins at its Glu and Arg residues, particularly binding to Glu via the metal ion-dependent adhesion site (MIDAS).